322 related articles for article (PubMed ID: 25735577)
1. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison S; Mollee P; Roberts A; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM
Intern Med J; 2015 Mar; 45(3):335-43. PubMed ID: 25735577
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison SJ; Mollee P; Roberts AW; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM
Intern Med J; 2015 Jan; 45(1):94-105. PubMed ID: 25582938
[TBL] [Abstract][Full Text] [Related]
3. Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Weber N; Mollee P; Augustson B; Brown R; Catley L; Gibson J; Harrison S; Ho PJ; Horvath N; Jaksic W; Joshua D; Quach H; Roberts AW; Spencer A; Szer J; Talaulikar D; To B; Zannettino A; Prince HM
Intern Med J; 2015 Apr; 45(4):371-82. PubMed ID: 25169210
[TBL] [Abstract][Full Text] [Related]
4. Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA; Richardson PG; Laubach JP; McCarthy PL
Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
[TBL] [Abstract][Full Text] [Related]
5. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
Moreau P; Giralt SA
Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
[TBL] [Abstract][Full Text] [Related]
6. Management of multiple myeloma in the newly diagnosed patient.
Mateos MV; San Miguel JF
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):498-507. PubMed ID: 29222298
[TBL] [Abstract][Full Text] [Related]
7. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
8. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Savini A; Alesiani F; Brunori M; Catarini M; Visani G; Samori A; Burattini M; Centurioni R; Montanari M; Fraticelli P; Ruggieri M; Falcioni S; Galieni P
Eur J Haematol; 2010 Jun; 84(6):474-83. PubMed ID: 20331733
[TBL] [Abstract][Full Text] [Related]
9. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
Kazandjian D; Mo CC; Landgren O; Richardson PG
Br J Haematol; 2020 Dec; 191(5):692-703. PubMed ID: 32501533
[TBL] [Abstract][Full Text] [Related]
10. How is patient care for multiple myeloma advancing?
Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
[TBL] [Abstract][Full Text] [Related]
11. New questions about transplantation in multiple myeloma.
Hari P; Pasquini MC; Vesole DH
Oncology (Williston Park); 2006 Sep; 20(10):1230-42; discussion 1242, 1244, 1249-50. PubMed ID: 17024872
[TBL] [Abstract][Full Text] [Related]
12. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Teh BW; Harrison SJ; Worth LJ; Thursky KA; Slavin MA
Eur J Cancer; 2016 Nov; 67():21-37. PubMed ID: 27592069
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy for multiple myeloma.
McCarthy PL; Palumbo A
Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well.
Martino M; Morabito F
Expert Opin Biol Ther; 2015 Feb; 15(2):149-54. PubMed ID: 25435056
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation beyond 60 years of age.
Jantunen E
Bone Marrow Transplant; 2006 Dec; 38(11):715-20. PubMed ID: 17041609
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma.
Röllig C; Knop S; Bornhäuser M
Lancet; 2015 May; 385(9983):2197-208. PubMed ID: 25540889
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma: future directions in autologous transplantation and novel agents.
Hari PN; McCarthy PL
Biol Blood Marrow Transplant; 2013 Jan; 19(1 Suppl):S20-5. PubMed ID: 23290439
[No Abstract] [Full Text] [Related]
19. [Treatment algorithms for multiple myeloma in Japan].
Ozaki S
Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience.
Er J; Routledge D; Hempton J; Wood C; Joyce T; Harrison S; Campbell P
Intern Med J; 2021 Feb; 51(2):280-283. PubMed ID: 33631863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
